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Introduction
Liposomes consist of closed assemblies of bilayers of lipid molecules with polar head groups and hydrophobic tails (Fig.  1a) . A. D. Bangham and R. W. Horne discovered liposomes (also referred to as unilamellar or multilamellar vesicles) during their electron microscopy investigations of phospholipids. 1 The immediate significance of the discovery was the realization by these authors that the structural resemblance, between liposomes and cell membranes, provided direct confirmation that the dominant component of biological membranes consists of lipid assemblies. To date, liposomes remain a vital component of model membrane studies aimed at elucidating the biological functions of membrane-associated proteins.
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Bangham's and Horne's work also showed that liposomes naturally confine hydrophobic molecules within their bilayer ( Fig. 1a) and form a permeability barrier for molecules entrapped within their aqueous interior. Within a decade of the initial discovery, researchers were investigating the potential of liposomes as carriers of drugs, peptides, proteins, and nucleic acids in therapeutic
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Kai Ewert studied chemistry at the Universität Bayreuth and obtained his Ph.D. from the Universität Stuttgart in 1998 for work on polymer chemistry and structure-function relationships. He joined the group of Prof. Safinya in 1999, first as a postdoc and later as a project scientist. His work centers on the design, synthesis and characterization of lipids, polymer-lipids, and peptidepolymer-lipids. applications. [3] [4] [5] A major early challenge in drug and gene delivery was the development of modified liposomes with long circulation times: bare drug-carrying liposomes are rapidly cleared by the mononuclear phagocytic system (immune cells) in in vivo settings. 6, 7 The initial attempt at developing long-circulating liposomes involved mimicking red blood cell (RBC) membranes, with the rationale being that immune cells do not attack RBCs under normal physiological conditions. This led to modification of the liposomal surface by addition of glycosphingolipids containing sialic acid groups. 8, 9 The final solution to this problem was the invention of PEGylated liposomes (so-called STEALTH® liposomes) that contain a coat of hydrophilic polymer resulting from the covalent attachment of poly(ethylene glycol) (PEG; e.g. 10 mol% of MW 2000 or 5 mol% of MW 5000) to the outer lipid headgroups (Fig. 1b) .
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In vivo studies demonstrated long circulating times of PEGylated liposomes, suggesting that blood plasma opsonins are excluded from the immediate vicinity of the liposome surface since this is a necessary event for removal by immune cells. [10] [11] [12] [13] [14] The PEG coat of STEALTH® liposomes induces a repulsive interaction (with a range on the scale of the size of the polymer chain [18] [19] [20] ), which results in the steric stabilization of liposomes. This prevents adhesion of other particles and also flocculation of liposomes into loose aggregates due to van der Waals attractions. [21] [22] [23] In the case of charged liposomes, the PEG coat effectively competes with and suppresses the adhesion of oppositely charged particles to the liposome. 24 The development of PEGylated liposomes led naturally to the synthesis and use of ligand-containing PEG-lipids for targeted delivery applications (Fig. 1b) . Currently, STEALTH® liposomes containing the chemotherapy drug doxorubicin-HCl (DOXIL) have been approved by the FDA for applications in certain cancers. 
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Structures of self-assembled cationic liposomenucleic acid complexes
A pioneering new approach for gene delivery was introduced by P. Felgner and co-workers, who complexed cationic liposomes (CLs) with long strands of gene-containing DNA. 26 The rationale for replacing the neutral or negative liposomes of earlier studies with CLs was the expectation that overall positively charged CL-DNA complexes would electrostatically adsorb to the sulfated, anionic proteoglycans coating mammalian cells, thus leading to more efficient complex uptake. The work by Felgner et al. was soon followed by numerous other groups, demonstrating gene expression in vivo in targeted organs 27 and in human clinical trials. 28 Gene carriers based on cationic lipids or polymers or a combination of these-rather than on engineered viruses-are now among the most promising technologies for transferring genes into cells for gene therapy and therapeutics. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] There are currently 113 ongoing gene therapy clinical trials worldwide using cationic liposomes (commonly referred to as lipofection) including those with added surface functionalities of steric stabilization and targeting ligands. 40 Felgner et al. hypothesized a "bead-on-string" structure for CL-DNA complexes in their seminal paper, 26, 41 picturing the DNA strand decorated with distinctly attached cationic liposomes. This original description of a highly disordered complex has turned out to be an oversimplification. Quantitative structural studies of CL-DNA complexes using synchrotron x-ray scattering have revealed that mixing of long strands of DNA with cationic liposomes leads to a topological transition from liposomes into collapsed condensates in the form of distinct liquid crystalline (LC) self-assemblies. [42] [43] [44] [45] [46] [47] [48] [49] The most common structure of CL-DNA complexes corresponds to DNA monolayers sandwiched between cationic membranes, thus forming the multilamellar Lα C phase. (Fig. 1c) for shedding of the PEG coat in the low-pH environment of late endosomes, in order for the complex to escape the endosome (discussed later). Fig. 2a depicts the local, nanometer-scale structure of the Lα C phase. We note that Lα C complexes may contain focal conic type II defects commonly observed in multilamellar phases [50] [51] [52] [53] (see cryo-TEM images in Fig. 5b ). Other self-assembled CL-DNA structures are the inverted hexagonal H II C phase, 43 with DNA encapsulated within cationic lipid monolayer tubes (Fig.  2b) , and the H I C phase, with hexagonally ordered DNA rods surrounded by cylindrical micelles (Fig. 2c ) that are formed from custom-synthesized lipids with highly charged (+16 e) dendritic multivalent headgroups (Fig. 2d ). The formation of CL-DNA structures with different membrane shapes is consistent with the predictions of the curvature elastic theory of membranes originally described by W. Helfrich, 54 after accounting for the differences in the shapes of the lipid molecules, which influence the spontaneous curvature (C 0 ) of membranes. [55] [56] [57] For example, lipids possessing a cylindrical shape such as the univalent cationic lipid DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) or the zwitterionic lipid DOPC (1,2-dioleoyl-sn-glycerophosphatidylcholine)-with a headgroup area approximately equal to the hydrophobic tail area-tend to self-assemble into lamellar structures with C 0 = 0. Lipids with a head group area smaller than their tail area, such as DOPE (1,2-dioleoyl-sn-glycerophosphatidylethanolamine), have an inverse cone shape and give rise to a negative spontaneous curvature C 0 < 0 and thus inverse hexagonal phases. Alternatively, lipids with a head group larger than their tail area (including custom-synthesized multivalent lipids with large headgroups 45 ) have a cone shape, resulting in hexagonal phases with membranes with a spontaneous curvature C 0 > 0. Synchrotron x-ray scattering shows that in most cases, the liquid crystalline structures of CL-DNA complexes is determined by the preferred curvature of the lipids constituting the cationic membranes. 42, 43, 45 Further studies are needed to characterize the structures and structural transitions between lamellar and non-lamellar phases in PEGylated CL-DNA complexes.
Transfection efficiency of distinct phases of cationic liposome-DNA complexes in vitro
Intensive worldwide research over the recent past including, in particular, studies involving custom synthesis of novel multivalent lipids (MVLs), has resulted in the development of promising lipid vectors with transfection efficiencies which under optimal conditions are competitive with viral vectors for in vitro studies. [29] [30] [31] [32] [33] [58] [59] [60] [61] [62] Fig. 3a shows transfection efficiency (TE; a measure of expression of an exogenous gene that is transferred into the cell by the lipid carrier) as a function of mol% cationic lipid for complexes transfecting mouse fibroblast cells at various MVL/DOPC ratios with the headgroup charge of the MVLs varied between +2 e and +5 e. TE data for monovalent DOTAP mixed with DOPC is also shown for comparison. Only the amount of neutral lipid was changed between data points, while the amount of DNA and the cationic lipid/DNA charge ratio of 2.8 were kept constant. 61 As the valence of the MVLs increases, TE tends to peak at a cationic lipid mol% lower than the 100% which early investigators had assumed would be the case. The origin of this optimal mol fraction for TE of lamellar complexes is made clear if one plots the TE data as a function of the membrane charge density (σ M ) of the complexes. The membrane charge density is defined as the total charge of the complex due to the MVLs divided by the total membrane area of the complex (consisting of a mixture of MVL and neutral lipids). . Synchrotron x-ray scattering shows that MVL-and DOTAP-based complexes used in these TE studies are in the lamellar Lα C phase. The collapse of the data on a single curve implies that σ M is a predictor of TE and a universal parameter for transfection by lamellar Lα C CL-DNA complexes.
A simple model of transfection by Lα C complexes 61, 63 can be used to explain the data of Fig. 3 . This model hypothesizes that the TE of complexes of low σ M is limited mostly because they are trapped in the endosome. Increases in σ M , leading to enhanced fusion of the cationic membrane of the complex with the anionic endosomal membrane, facilitate nucleic acid delivery to the cytosol and thus enhance TE (Fig. 3b , labeled Regime I). At very high σ M (Regime III), complexes escape the endosome but a fraction of the DNA remains trapped in complexes in the cytoplasm due to the strong electrostatic interactions between cationic membranes and DNA. Thus, increases in σ M lead to decreases in TE in this regime III. Regime II is the regime of compromise, where the optimal σ M is large enough for many complexes to escape the endosome and yet small enough to allow a larger fraction of DNA to be released from complexes (compared to Regime III). Transfection efficiency of non-lamellar CL-DNA complexes is very different from the universal behavior found for lamellar complexes. The high TE of DOTAP/DOPE H II C complexes (Fig. 3b, open circles) , which is independent of σ M , is likely related to the readily occurring fusion of the membranes of H II C complexes with the cell's plasma and endosomal membranes, observed in 3D confocal microscopy experiments. 63 Complexes in the H I C phase of MVLs with very large headgroups (e.g. the cone-shaped lipid MVLBG2 (+16 e)) also show high TE that is independent of σ M . 45, 64 Further studies will be required to clarify the mechanism of transfection of non-lamellar complexes where their TE behavior deviates from the bellshaped curve observed for lamellar complexes.
siRNA embedded in a cationic gyroid cubic lipid matrix for gene silencing
The discovery of RNA interference (RNAi) as a posttranscriptional gene-silencing pathway has given rise to a major new branch in cationic lipid-based nucleic acid research worldwide. [65] [66] [67] [68] [69] [70] [71] Upon complexation with cationic liposomes, short strands of double-stranded RNA (referred to as short interfering RNA, siRNA), evoke the RNA interference pathway leading to sequence-specific gene silencing. [72] [73] [74] [75] In addition to its widespread application in functional genomics, siRNA technology promises to revolutionize biotechnology and therapeutics. 71 The current limiting step in siRNA gene silencing technology is the development of efficient carriers of siRNA, in particular for in vivo applications. 74 Previous to the development of siRNA technology, researchers had in fact utilized single-strand antisense oligonucleotides in therapeutic applications. 36 These technologies are currently being optimized further. A recent synchrotron x-ray scattering study showed that a thermodynamically stable double-gyroid cubic lipid phase incorporating siRNA may be formed both with monovalent DOTAP and multivalent MVL5 when they are mixed with the neutral lipid GMO (1-monooleoyl-glycerol) (Fig. 4a) . 76, 77 The study, which followed a rational design of the elastic properties of the carrier lipid membrane, revealed that the cubic CLsiRNA complex phase (labeled Q II G, siRNA ) is remarkably efficient at cytoplasmic delivery and subsequent gene silencing. Notably, this was the first demonstration of CL-siRNA complexes showing highly efficient sequence-specific gene knockdown (K T ) and low nonspecific silencing (K NS ) (Fig. 4b) at low membrane charge density, which demonstrated that high silencing efficiency does not mandate high membrane charge density. (The previous studies of lamellar CL-siRNA complexes only showed high specific silencing efficiency at relatively high membrane charge density. 72, 73 ) Fig. 4 (a) The unit cell of the double-gyroid cubic phase (space group Ia3d) incorporating siRNA within its two water channels (green and orange). The discovered properties of the Q II G, siRNA phase are consistent with the hypothesis that the lipids of the gyroid cubic phase favor membrane pore formation resulting from fusion of the membranes of the gyroid CL-siRNA complex and endosomal membranes. Pores, in turn, allow for cytoplasmic siRNA delivery. This inclination to pore formation arises because the surface of membrane pores and the surface of the gyroid cubic phase are both characterized by a negative Gaussian curvature.
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Surface-functionalized cationic liposome-DNA nanoparticles
The CL-nucleic acid complexes that we have described so far are suitable for transfection experiments in vitro (including transfection of hard-to-transfect cells), but not ideal for in vivo clinical studies because the overall positive charge of the complex results in their early clearance from circulation by immune cells through the mechanism of opsonization. [10] [11] [12] [13] [14] [15] [16] [17] As was discussed earlier in the context of unilamellar liposome delivery (see introduction), steric stabilization of complexes by addition of PEG-lipids (Fig. 5a ), suppresses attachment of (overall anionic) serum opsonins, thus prolonging circulation times. [18] [19] [20] Therefore, in vivo applications require the development of PEGylated CL-nucleic acid complexes with optimized TE in vitro. Dynamic light scattering measurements show that PEGylated CL-DNA complexes containing 10 mol% PEG2K-lipid (PEG molecular weight of 2000 Da) form sterically stable nanoparticles (NPs) with an average diameter ≈ 100 nm. 81 Cryogenic TEM of lamellar CL-DNA complexes in 50 mM NaCl further shows that while uncoated complexes aggregate (Fig. 5b) , PEGylated CL-DNA NPs are sterically stabilized and retain their distinct size (≈ 100 nm) and morphology even after centrifugation (Fig. 5c) . The TEM images are consistent with a recent synchrotron x-ray scattering study of the pathways of formation of lamellar PEGylated CL-DNA complexes, which showed that the NPs contain a significant numbers of bilayers at 50 mM and 100 mM NaCl (between 10 and 20 on average, at high membrane charge density and 10 mol% PEG2K-lipid). 49 The same study showed that the NPs contain, on average, only a few bilayers if the complexation occurs at 150 mM NaCl. PEGylated CL-DNA NPs exhibit reduced TE because the weak electrostatic adhesion of the NPs to the negative surface of cells dramatically reduces uptake of NPs by cells. TE drops between two and three orders of magnitude with the incorporation of 10 mol% PEG2K-lipid. 21, 81, 82 Cell attachment and uptake of PEGylated NPs may be recovered by covalent attachment of a linear RGD peptide ligand (GRGDSP) to the distal end of the PEG2K-lipid. Custom synthesis again plays a crucial role in these studies, where the RGD-PEG2K-lipid was prepared by solid phase peptide synthesis methods employing a custom-synthesized carboxy-terminated PEG2K-lipid in the final coupling step to the N-terminus of the protected peptide on the resin. 81 The linear RGD peptide binds to integrins (e.g. α v β 3 and α v β 5 ) on the cell's surface, providing receptor-mediated endocytosis. [83] [84] [85] Aside from linear RGD moieties, many current studies incorporate cyclic RGD peptides which tend to have much higher binding affinities to integrins and are more selective. Although the preparation in (c) (showing coexistence of nanometer scale complexes (solid arrow) with unilamellar cationic liposomes (dashed arrow)) has been extensively centrifuged, steric stabilization due to the PEG2K coat prevents aggregation. Scale bars correspond to 100 nm.
Reprinted from reference 81, with permission from Elsevier.
Live-cell imaging at low membrane charge density (to fully suppress cell attachment/uptake due to electrostatic interactions), combined with quantitative particle tracking of the intracellular distribution of complexes, directly confirms the increased rate and total amount of NP uptake when PEG2K-lipid is replaced by RGD-PEG2K-lipid (Fig. 6) . 81 NPs containing 10 mol% PEG2K-lipid show nearly no uptake in live-cell imaging even 5 hours after addition of NPs to cells (Fig. 6a) . In contrast, NPs containing linear RGD-PEG2K-lipid exhibit significantly increased surface attachment at 1 hour, followed by significant internalization at the 5 hour mark (Fig.  6b) . TE data show that surface-functionalized complexes containing 10 mol% RGD-PEG2K-lipid partially recover the loss of TE induced by PEGylation. This indicates that while RGD-containing NPs have efficiently undergone receptormediated cell attachment and uptake (consistent with the livecell imaging data), endosomal entrapment remains a significant barrier. Future surface functionalization is expected to ensure that the uptake of NPs with cell targeting ligands ultimately leads to endosomal release of a majority of NPs. As a first test of this concept, recent custom synthesis of PEG-lipids containing acid-labile moieties (see cartoon in Fig. 1c ) has been shown to aid in shredding of the PEG coat of NPs by hydrolysis in the low-pH environment of late endosomes, thus facilitating endosomal escape and delivery of high membrane charge density NPs to the cytosol. 82 We expect to see significant research progress in the near future in the development of a variety of functionalized lipid NPs for therapeutic purposes employing concepts along the lines of what we have described. Indeed, among the largest current efforts by numerous groups worldwide is the development of lipid NP carriers of drugs for clinical cancer chemotherapy applications.
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Conclusions and perspectives
An important objective in this biomedical research area is to develop a scientific understanding, which will enable the design and synthesis of optimal lipid nanoparticle carriers of DNA and siRNA for gene therapeutics and disease control. To this end, the work we have presented in this review has emphasized a rational design approach for tuning the physico-chemical and elastic properties of cationic membranes in order to overcome cellular barriers to nucleic acid delivery. A significant finding relates to the discovery of distinct structures of CL-nucleic acid complexes by synchrotron x-ray scattering and the discovery that the structures correlate with delivery mechanisms and transfection and silencing is independent of σ M . We presented data showing that gyroid cubic CL-siRNA complexes exhibit improved silencing efficiency because of the cubic membrane's inherent fusogenic properties which facilitate endosomal escape even at low σ M . A significant success coming out of the research efforts on lipid vectors is that transfection efficiencies of multivalent lipid vectors are now competitive with viral vectors in vitro; indeed, the multivalent lipid MVL5 (originally synthesized and characterized at UC Santa Barbara) has been recently commercialized by Avanti Polar Lipids, Inc. (Alabaster, AL, USA) as an efficient transfection reagent for gene silencing with low toxicity.
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Finally, we note that current research on lipid-based vectors is heavily focused on producing nanoparticles [92] [93] [94] [95] that will be suitable for in vivo delivery. 81, 82, 96, 97 We expect that continued mechanistic studies by many laboratories worldwide of distinct strategies for cell targeting and endosomal escape, which incorporate custom synthesis for obtaining new rationally modified nanoparticle carriers, will positively impact the large number of gene therapy clinical trials which utilize lipids.
